Profilo
Richard Chesworth worked as Senior Vice President-Research at Epizyme, Inc. and as Chief Scientific Officer at Kymera Therapeutics, Inc. He holds a doctorate degree from the University of Oxford and an undergraduate degree from Imperial College London.
Precedenti posizioni note di Richard Chesworth
| Società | Posizione | Fine |
|---|---|---|
| KYMERA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 22/10/2021 |
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | - |
Formazione di Richard Chesworth
| University of Oxford | Doctorate Degree |
| Imperial College London | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Richard Chesworth
